Company intelligence / Profile preview

AI Biomedical

Ownership: Private
Development stage: Preclinical

Overview

AI Biomedical has developed an end-to-end automated cell manufacturing system powered by artificial intelligence to streamline and reduce the cost of producing regenerative medicine products. The company positions itself as a design and automation leader in this space, aiming to address high costs and scalability challenges in cell therapy production. No clinical trial results are reported as the company is not directly developing therapeutic assets.

Therapeutic areas: Other
Modalities: Cell therapyAutomated cell manufacturing systems
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on AI Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI Biomedical.

Explore the full profile